Pendal Group’s Autolus Therapeutics AUTL Stock Holding History

Pendal Group’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$3.29M	Buy	1,733,391 +362,634	+26%	+$917K	0.03%	181
2022 Q3	$2.93M	Buy	1,370,757 +5,328	+0.4%	+$15.8K	0.03%	176
2022 Q2	$3.86M	Sell	1,365,429 -9,677	-0.7%	-$29.4K	0.04%	152
2022 Q1	$5.73M	Sell	1,375,106 -69,696	-5%	-$293K	0.05%	141
2021 Q4	$7.5M	Buy	1,444,802 +36,485	+3%	+$219K	0.06%	127
2021 Q3	$9.22M	Buy	1,408,317 +875,067	+164%	+$5.53M	0.08%	119
2021 Q2	$4.6M	Buy	533,250 +411,685	+339%	+$2.56M	0.04%	151
2021 Q1	$1.05M	Buy	121,565 +71,211	+141%	+$527K	0.01%	313
2020 Q4	$450K	Buy	+50,354	New	+$537K	﹤0.01%	384

Other funds holding AUTL

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

OAMG

Odey Asset Management Group London, United Kingdom $381M AUM 45.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Pendal Group's AUTL Position: Q4 2022 in Review

Pendal Group increased its Autolus Therapeutics (AUTL) stake by 26% in Q4 2022, buying an estimated $917K and bringing the position to 1,733,391 shares worth $3.29M. The position accounts for 0.03% of the portfolio, ranked #181.

Pendal Group first reported a position in AUTL in Q4 2020 and has held it in 9 quarters since. The position peaked at $9.22M in Q3 2021. 71 funds tracked by Wall St. Rank hold AUTL as of Q4 2022.

Pendal Group held 1,733,391 shares of Autolus Therapeutics worth $3.29M as of Q4 2022.
Pendal Group bought 362,634 Autolus Therapeutics shares in Q4 2022, an estimated $917K.
Autolus Therapeutics made up 0.03% of Pendal Group's portfolio in Q4 2022, its #181 holding.
Pendal Group first reported a position in Autolus Therapeutics in Q4 2020 and has held it in 9 quarters since.
Pendal Group's Autolus Therapeutics position peaked at $9.22M in Q3 2021.
71 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2022.

Based on Pendal Group's 13F filing for Q4 2022, filed 19 Jan 2023.